Oxidative Stress in Parkinson's Disease: Potential Benefits of Antioxidant Supplementation
- PMID: 33101584
- PMCID: PMC7576349
- DOI: 10.1155/2020/2360872
Oxidative Stress in Parkinson's Disease: Potential Benefits of Antioxidant Supplementation
Abstract
Parkinson's disease (PD) occurs in approximately 1% of the population over 65 years of age and has become increasingly more common with advances in age. The number of individuals older than 60 years has been increasing in modern societies, as well as life expectancy in developing countries; therefore, PD may pose an impact on the economic, social, and health structures of these countries. Oxidative stress is highlighted as an important factor in the genesis of PD, involving several enzymes and signaling molecules in the underlying mechanisms of the disease. This review presents updated data on the involvement of oxidative stress in the disease, as well as the use of antioxidant supplements in its therapy.
Copyright © 2020 Sandro Percário et al.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.Biochim Biophys Acta. 2014 Aug;1842(8):1282-94. doi: 10.1016/j.bbadis.2013.09.007. Epub 2013 Sep 20. Biochim Biophys Acta. 2014. PMID: 24060637 Free PMC article. Review.
-
The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson's disease: a review.Int J Neurosci. 2011 Feb;121(2):51-7. doi: 10.3109/00207454.2010.535934. Epub 2010 Dec 2. Int J Neurosci. 2011. PMID: 21126109 Review.
-
Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.CNS Neurol Disord Drug Targets. 2016;15(1):45-53. doi: 10.2174/1871527314666150821103306. CNS Neurol Disord Drug Targets. 2016. PMID: 26553164 Review.
-
Terpene compounds in nature: a review of their potential antioxidant activity.Curr Med Chem. 2012;19(31):5319-41. doi: 10.2174/092986712803833335. Curr Med Chem. 2012. PMID: 22963623 Review.
-
Antioxidants as therapy for Parkinson's disease.Antioxid Redox Signal. 2005 May-Jun;7(5-6):694-700. doi: 10.1089/ars.2005.7.694. Antioxid Redox Signal. 2005. PMID: 15890014 Review. No abstract available.
Cited by
-
Honey and levodopa comparably preserved substantia nigra pars compacta neurons through the modulation of nuclear factor erythroid 2-related factor 2 signaling pathway in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease model.Anat Cell Biol. 2024 Sep 30;57(3):431-445. doi: 10.5115/acb.24.034. Epub 2024 Jul 12. Anat Cell Biol. 2024. PMID: 38992924 Free PMC article.
-
Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease.Front Pharmacol. 2022 Sep 12;13:977521. doi: 10.3389/fphar.2022.977521. eCollection 2022. Front Pharmacol. 2022. PMID: 36172194 Free PMC article. Review.
-
Ti3C2 nanosheets with broad-spectrum antioxidant activity for cytoprotection against oxidative stress.RSC Adv. 2022 Apr 8;12(18):11128-11138. doi: 10.1039/d2ra01225a. eCollection 2022 Apr 7. RSC Adv. 2022. PMID: 35425035 Free PMC article.
-
6-Hydroxy-2,2,4-trimethyl-1,2,3,4-tetrahydroquinoline Alleviates Oxidative Stress and NF-κB-Mediated Inflammation in Rats with Experimental Parkinson's Disease.Curr Issues Mol Biol. 2023 Sep 21;45(9):7653-7667. doi: 10.3390/cimb45090483. Curr Issues Mol Biol. 2023. PMID: 37754267 Free PMC article.
-
Loliolide, a New Therapeutic Option for Neurological Diseases? In Vitro Neuroprotective and Anti-Inflammatory Activities of a Monoterpenoid Lactone Isolated from Codium tomentosum.Int J Mol Sci. 2021 Feb 14;22(4):1888. doi: 10.3390/ijms22041888. Int J Mol Sci. 2021. PMID: 33672866 Free PMC article.
References
-
- Limongi J. C. P. Conhecendo Melhor a Doença de Parkinson – Uma Abordagem Multidisciplinar com Orientações Práticas para o Dia-a-Dia. São Paulo: Plexius; 2001.
-
- Teive H. A. G., Meneses M. S. Histórico. In: Meneses M. S., Teive H. A. G., editors. Doença de Parkinson: Aspectos Clínicos e Cirúrgicos. Rio de Janeiro: Guanabara Koogan; 1996. pp. 4–14.
-
- Silberman C. D., Laks J., Rodrigues C. S., Engelhardt E. A review of depression as a risk factor of Parkinson’s disease and impact cognition. Revista de Psiquiatria do Rio Grande do Sul. 2004;26(1):52–60.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical